ERBB2 and breast carcinoma: Oncotype DX® (Genomic Health, Redwood City, CA, USA), MammaPrint® (Agendia, Irvine, CA, USA), EndoPredict® (Myriad Genetics, Salt Lake City, UT, USA), and Prosigna® (NanoString Technologies, Seattle, WA, USA) provide risk scores with prognostic information for distant recurrence in patients with luminal A-like and luminal B-like (HER2-negative) breast cancers.